Shikshya Shrestha

Shikshya Shrestha

Auto-generated profile, based on publicly available information

Shikshya Shrestha

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2017 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
QNQ Nie
Q Nie
SSS Shrestha
S Shrestha
ETEe Tapper
Ee Tapper
CTCs Trogstad‐Isaacson
Cs Trogstad‐Isaacson
KBKj Bouchonville
Kj Bouchonville
RDRb Diasio
Rb Diasio

11 October 2016 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
TET Elraiyah
T Elraiyah
CJCr Jerde
Cr Jerde
SSS Shrestha
S Shrestha
RWR Wu
R Wu
QNQ Nie
Q Nie
RDRb Diasio
Rb Diasio

31 October 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
RWRentian Wu
Rentian Wu
QNQian Nie
Qian Nie
ETErin E. Tapper
Erin E. Tapper
CJCalvin R. Jerde
Calvin R. Jerde
GDGarrett S. Dunlap
Garrett S. Dunlap
RDRobert B. Diasio
Robert B. Diasio
The antimetabolite 5-fluorouracil (5-FU) is one of the most widely used chemotherapy drugs. Dihydropyrimidine dehydrogenase (DPD) is a major determinant of 5-FU response and toxicity. Although DPYD variants may affect 5-FU metabolism, they do not completely explain the reported variability in DPD function or the resultant differences in treatment response. Here, we report that H3K27 trimethylation (H3K27me3) at the DPYD promoter regulated by Ezh2 and UTX suppresses DPYD expression by inhibiting transcription factor PU.1 binding, leading to increased resistance to 5-FU. Enrichment of H3K27me3 at the DPYD promoter was negatively correlated with both DPYD expression and DPD enzyme activity in peripheral blood specimens from healthy volunteers. Lastly, tumor expression data suggest that DPYD repression by Ezh2 predicts poor survival in 5-FU–treated cancers. Collectively, the findings of the present article suggest that a previously uncharacterized mechanism regulates DPD expression and may contribute to tumor resistance to 5-FU. Cancer Res; 76(21); 6362–73. ©2016 AACR.

24 March 2016 in Medical Epigenetics
Verified
Journal Article
Open access
PDF file
SSShikshya Shrestha
Shikshya Shrestha
SOSteven M. Offer
Steven M. Offer
The GABAergic neurotransmission is a highly conserved system that has been attributed to various regulatory events. There has been a notable number of studies on the importance of GABAergic neurotransmission, both excitatory and inhibitory, in neurogenesis and central nervous system development including its control of neuronal cell proliferation and migration, synaptogenesis, dendrite formation and branching, and new neuronal cell integration in the adult brain. There has been remarkable progress in understanding the epigenetic regulations of GABAergic genes and their aberrant expressions in various neurological disorders such as autism spectrum disorder, Rett's syndrome, schizophrenia and PWS. The roles of histone modifications, chromatin looping and gene methylation have been implicated in altered regulations of key genes in the GABAergic pathway. Taken together, they affect the functioning of GABAergic neurotransmission and disrupt various events in brain development. Here, we focus on the role of GABAergic neurotransmission in brain development and on how various genetic and epigenetic events regulate the GABAergic genes in pre- and postnatal brain. We also discuss how these regulatory mechanisms contribute to the pathogenesis of neurological disorders and, therefore, can be used in the development of potential epigenetic therapy for these diseases.

22 November 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
JIJewel Imani
Jewel Imani
KLKaifeng Liu
Kaifeng Liu
YCYe Cui
Ye Cui
JAJean-Pierre Assaker
Jean-Pierre Assaker
JHJunwen Han
Junwen Han
SESouheil El-Chemaly
Souheil El-Chemaly
Lung allograft rejection results in the accumulation of low–molecular weight hyaluronic acid (LMW-HA), which further propagates inflammation and tissue injury. We have previously shown that therapeutic lymphangiogenesis in a murine model of lung allograft rejection reduced tissue LMW-HA and was associated with improved transplant outcomes. Herein, we investigated the use of 4-Methylumbelliferone (4MU), a known inhibitor of HA synthesis, to alleviate acute allograft rejection in a murine model of lung transplantation. We found that treating mice with 4MU from days 20 to 30 after transplant was sufficient to significantly improve outcomes, characterized by a reduction in T cell–mediated lung inflammation and LMW-HA content and in improved pathology scores. In vitro, 4MU directly attenuated activation, proliferation, and differentiation of naive CD4 + T cells into Th1 cells. As 4MU has already been demonstrated to be safe for human use, we believe examining 4MU for the treatment of acute lung allograft rejection may be of clinical significance.

21 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ACAndrew M. Courtwright
Andrew M. Courtwright
ALAnthony M. Lamattina
Anthony M. Lamattina
PLPierce H. Louis
Pierce H. Louis
ATAnil J. Trindade
Anil J. Trindade
PBPatrick Burkett
Patrick Burkett
SESouheil El-Chemaly
Souheil El-Chemaly
Hyaluronan (HA) is associated with innate immune response activation and may be a marker of allograft dysfunction in lung transplant recipients. This was a prospective, single center study comparing levels of bronchioalveolar lavage (BAL) and serum HA and the HA immobilizer LYVE-1 in lung transplant recipients with and without acute cellular rejection (ACR). Chronic lung allograft dysfunction (CLAD)-free survival was also evaluated based on HA and LYVE-1 levels. 78 recipients were enrolled with a total of 115 diagnostic biopsies and 1.5 years of median follow-up. Serum HA was correlated with BAL HA (r = 0.25, p = 0.01) and with serum LYVE-1 (r = 0.32, p = 0.002). There was significant variation in HA and LYVE-1 over time, regardless of ACR status. Levels of serum HA (median 74.7 vs 82.7, p = 0.69), BAL HA (median 149.4 vs 134.5, p = 0.39), and LYVE-1 (mean 190.2 vs 183.8, p = 0.72) were not associated with ACR. CLAD-free survival was not different in recipients with any episode of elevated serum HA (HR = 1.5, 95% CI = 0.3–7.7, p = 0.61) or BAL HA (HR = 0.94, 95% CI = 0.2–3.6, p = 0.93). These results did not differ when stratified by bilateral transplant status. In this small cohort, serum HA, BAL HA, and LYVE-1 levels are not associated with ACR or CLAD-free survival in lung transplant recipients.